Three of Oklo’s top executives sold over $21 million in stock on April 1, 2026, all under pre-arranged Rule 10b5-1 trading plans.
CEO Jacob DeWitte sold stock at weighted average prices between $48.41 and $51.20 per share, totaling $10,069,852. After the sale, he directly holds 691,533 Class A shares and indirectly holds over 20 million more.
COO and co-founder Caroline Cochran also sold stock totaling $10,069,852, at prices ranging from roughly $47.99 to $51.79 per share. She directly owns 658,039 shares following the transaction.
CFO Richard Bealmear sold 16,342 shares at $51.08, bringing in $834,749. He retains 386,008 Class A shares.
All three sales were conducted under 10b5-1 plans, which are set up in advance to avoid accusations of trading on inside information.
But the April 1 sales are just part of a broader pattern for DeWitte. He has been selling Oklo stock repeatedly since January, including trades at around $112, $75, and $63 per share. In total, DeWitte has generated tens of millions in proceeds from these sales over the past few months.
The April 1 sale alone — 200,000 shares across two transactions — represented a 17.58% reduction in his direct holdings.
The insider selling comes alongside some pointed commentary from CNBC’s Jim Cramer. When asked about Oklo on a recent episode, Cramer didn’t hold back: “Oklo, while not a science project, has very little prospects for making any money any time in the future that we think is important for a stock.”
He had made similar comments in January, calling Oklo “not a commercial enterprise” and arguing that while nuclear power has a future, companies like GE Vernova — with actual commercial operations — are better positioned than Oklo right now.
On the fundamentals side, Oklo reported a loss of $0.27 per share for its most recent quarter, missing the consensus estimate of -$0.17 by $0.10.
Analysts are still broadly bullish, but price targets have come down. UBS cut its target from $95 to $60 and rated the stock neutral. Needham dropped its target from $135 to $73, while Canaccord cut from $175 to $125. Cantor Fitzgerald held its overweight rating with a $122 target.
The average analyst price target currently sits at $84.30, with a consensus rating of “Moderate Buy.” Two analysts have a Strong Buy, nine have Buy, six have Hold, and two have Sell ratings.
Oklo’s stock has a 12-month range of $17.42 to $193.84, with the 50-day moving average at $64.62 and the 200-day at $93.16.
The post Oklo Stock: Insiders Sell Over $21M As Cramer Turns Bearish – Here’s Why appeared first on CoinCentral.
